Catabasis Pharma (CATB) Tops Q2 EPS by 4c

Catabasis Pharma (NASDAQ: CATB) reported Q2 EPS of ($0.61), $0.04 better than the analyst estimate of ($0.65).

For earnings history and earnings-related data on Catabasis Pharma (CATB) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery